Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Update

Vivos Therapeutics, Inc. (NASDAQ:VVOS) saw a large growth in short interest during the month of August. As of August 31st, there was short interest totaling 2,503,479 shares, a growth of 100.4% from the August 15th total of 1,249,260 shares. Based on an average trading volume of 49,532,777 shares, the short-interest ratio is presently 0.1 days. Currently, 18.4% of the shares of the stock are short sold.

Vivos Therapeutics Trading Down 4.3%

Shares of NASDAQ:VVOS traded down $0.01 during trading on Monday, reaching $0.18. The company had a trading volume of 902,926 shares, compared to its average volume of 4,703,563. The stock has a market capitalization of $2.45 million, a P/E ratio of -0.09 and a beta of 6.04. Vivos Therapeutics has a 12 month low of $0.16 and a 12 month high of $3.70. The company has a fifty day moving average of $0.33 and a two-hundred day moving average of $0.71.

Vivos Therapeutics (NASDAQ:VVOS) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.10. The firm had revenue of $5.15 million during the quarter, compared to analyst estimates of $5.63 million. Vivos Therapeutics had a negative return on equity of 2,325.64% and a negative net margin of 122.00%. As a group, equities research analysts predict that Vivos Therapeutics will post -1.54 earnings per share for the current year.

Institutional Trading of Vivos Therapeutics

Institutional investors have recently made changes to their positions in the stock. Acorn Wealth Advisors LLC purchased a new stake in Vivos Therapeutics in the 4th quarter worth approximately $30,000. XTX Topco Ltd purchased a new stake in Vivos Therapeutics in the second quarter worth $65,000. Sequoia Financial Advisors LLC purchased a new stake in Vivos Therapeutics in the first quarter worth $28,000. B. Riley Wealth Advisors Inc. bought a new stake in Vivos Therapeutics in the second quarter valued at $220,000. Finally, DRW Securities LLC boosted its holdings in Vivos Therapeutics by 179.5% in the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after acquiring an additional 74,441 shares in the last quarter. Hedge funds and other institutional investors own 26.35% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on VVOS shares. Ascendiant Capital Markets boosted their price target on Vivos Therapeutics from $3.00 to $3.10 and gave the stock a “buy” rating in a report on Thursday, June 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $2.80.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.